Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05627635 |
TitleFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2022-11-25 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT04041310 |
TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2019-08-01 |
Location
California, United States
Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05990543 |
TitleCombination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2023-08-14 |
Location
South Korea
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nelmastobart and Capecitabine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06011772 |
TitleA Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | Phase
Early Phase 1
|
Date Added 2023-08-25 |
Location
New York, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06034860 |
TitleStudy of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Phase
Phase 1
|
Date Added 2023-09-13 |
Location
California, United States
Indiana, United States Missouri, United States New York, United States Virginia, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
MT-8421, Nivolumab, Opdivo |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06105021 |
TitlePhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Phase
Phase 1, Phase 2
|
Date Added 2023-10-27 |
Location
California, United States
Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AFNT-211 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06106308 |
TitleStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Phase
Phase 2
|
Date Added 2023-10-30 |
Location
Arizona, United States
Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, FOLFIRI, FOLFOX, Onvansertib |
Tags
MSS/ MMRp
|
| NCT ID NCT06107413 |
TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | Phase
Phase 2
|
Date Added 2023-10-30 |
Location
Arizona, United States
Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States Oregon, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan South Korea Spain Taiwan |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan |
Tags
MSS/ MMRp
|
| NCT ID NCT03223779 |
TitleStudy of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2017-07-21 |
Location
Massachusetts, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05879822 |
TitleA Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Phase
Phase 2
|
Date Added 2023-05-30 |
Location
Brazil
China Georgia Greece Hungary New Zealand Romania South Africa Turkey (Türkiye) |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
INCB099280 |
Tags
MSI-H/ MMRd
|
